Ignite Creation Date:
2024-05-06 @ 6:58 PM
Last Modification Date:
2024-10-26 @ 2:58 PM
Study NCT ID:
NCT05856383
Status:
RECRUITING
Last Update Posted:
2023-05-12
First Post:
2023-04-02
Brief Title:
Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABC
Sponsor:
Zhejiang Cancer Hospital
Organization:
Zhejiang Cancer Hospital
Study Overview
Official Title:
Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in the Treatment of Advanced Breast Cancer
Status:
RECRUITING
Status Verified Date:
2023-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
HER2-VIP
Brief Summary:
This is a prospective no interventional single arm cohort study which aims to study the efficacy and safety of inetetamab combined with pyrotinib and vinorelbine in the Treatment of HER2 positive advanced breast cancer in the real world The study will be conducted by signing an informed consent form for study enrollment collecting patient case information and conducting observation and follow-up
Detailed Description:
This is a prospective no interventional single arm cohort study which aims to study the efficacy and safety of inetetamab combined with pyrotinib and vinorelbine in the Treatment of HER2 positive advanced breast cancer in the real world The study will be conducted by signing an informed consent form for study enrollment collecting patient case information and conducting observation and follow-upThe research process is divided into screening period treatment period and survival and follow-up periods
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None